NeoGenomics Presents RaDaR Assay Data at 2025 SABCS for Breast Cancer Monitoring
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 59 minutes ago0mins
- Research Presentation: NeoGenomics will showcase new data on its RaDaR®1.0 assay at the 2025 SABCS, emphasizing its critical role in monitoring molecular residual disease in early breast cancer, which could advance precision medicine.
- Clinical Trial Progress: The SURVIVE HERoes Phase III trial will explore the application of RaDaR testing in molecular relapse monitoring, and positive results could provide new strategies for personalized treatment, enhancing patient survival rates.
- Long-term Tracking Study: Five-year follow-up data from the CLEVER trial show that RaDaR-detected ctDNA is often present months before clinical recurrence, highlighting its potential in monitoring long-term risks and possibly changing standards for post-treatment care in breast cancer.
- Industry Impact: CEO Tony Zook stated that these studies provide crucial evidence for integrating MRD insights into routine oncology care, potentially enhancing the treatment capabilities of community oncologists.
NEO.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on NEO
Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is 13.67 USD with a low forecast of 11.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 11.710
Low
11.00
Averages
13.67
High
17.00
Current: 11.710
Low
11.00
Averages
13.67
High
17.00
Piper Sandler
Overweight
maintain
$11 -> $12
2025-11-10
Reason
Piper Sandler
Price Target
$11 -> $12
2025-11-10
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on NeoGenomics to $12 from $11 following quarterly results. The firm keeps an Overweight rating on the shares.
BofA
Neutral
maintain
$11
2025-10-29
Reason
BofA
Price Target
$11
2025-10-29
maintain
Neutral
Reason
BofA raised the firm's price target on NeoGenomics to $11 from $6.50 and keeps a Neutral rating on the shares after "a solid quarter." The firm views the quarterly update as "constructive," but sees questions on the sustainability of the growth rate and the competitive position, the analyst tells investors.
Leerink
Market Perform
maintain
$12 -> $14
2025-10-28
Reason
Leerink
Price Target
$12 -> $14
2025-10-28
maintain
Market Perform
Reason
Leerink raised the firm's price target on NeoGenomics to $14 from $12 and keeps a Market Perform rating on the shares. The company reported a Q3 beat and is taking investor feedback by proving "beatable guidance and realistic targets," the analyst tells investors in a research note.
TD Cowen
Buy
upgrade
$10 -> $12
2025-09-12
Reason
TD Cowen
Price Target
$10 -> $12
2025-09-12
upgrade
Buy
Reason
TD Cowen raised the firm's price target on NeoGenomics to $12 from $10 and keeps a Buy rating on the shares after hosting meetings with management. The firm left more constructive on NeoGenomics's new product launches, saying MolDX reimbursement remains the "final gate" for a 2026 ramp.
See All Ratings
About NEO
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is Comprehensive Genomic Profiling (CGP) and its role in diagnostics?
How does CGP improve early identification of myeloid malignancies?
How might NeoGenomics' CGP technology impact future cancer diagnostic practices?
Will the identification of rare fusions like PDGFRA lead to new therapies?